Drugs / Alomfilimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03829501 | Jan 2019 → Oct 2024 | cervical cancer, esophageal cancer, gastric cancer, head and neck squamous cell carcinoma +7 | Kymab Limited | Terminated | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alomfilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03829501 ↗ |
| Known as | KY-1044 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650484 ↗ |
| Known as | SAR-445256 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650484 ↗ |
| Modality | Monoclonal antibody | “A human anti-ICOS monoclonal antibody” NCT03829501 ↗ |
| Route | Intravenous | “via intravenous (IV) infusion” NCT03829501 ↗ |
| Target | ICOS | “anti-ICOS antibody” PMID 42259602 ↗ Jun 2026 |